Home › Funds › Parkman Healthcare Partners LLC › MBX

Parkman Healthcare Partners LLC position in MBX

MBX BIOSCIENCES INC · Health Care

Parkman Healthcare Partners LLC reported holding 716,542 shares of MBX (MBX BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$42.0M, representing 3.79% of its reported portfolio and ranking #3 among its reported holdings. Parkman Healthcare Partners LLC has disclosed MBX holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

Latest position (Q3 2026)716.54K sh
Reported value held$42.00M
Portfolio Weight3.79%
First reportedQ4 2024
Last changeReduce
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How Parkman Healthcare Partners LLC's MBX position evolved

Parkman Healthcare Partners LLC first disclosed a stake in MBX in Q4 2024 at 170,000 shares (US$3.1M). The position peaked in Q2 2026 at 800,173 shares, worth US$44.2M. Across 8 filings, Parkman Healthcare Partners LLC increased the stake 3 time(s), trimmed it 3 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 716,542 shares valued at US$42.0M — a reduction of -83,631 shares quarter over quarter.. Notable position changes include a 93% increase in Q1 2025 (shares rose 55% over the following quarter), a 166% increase in Q2 2025 (shares rose 53% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2024 170.00K $3.13M New
Q1 2025 328.32K $2.42M Add
Q2 2025 871.93K $9.95M Add
Q3 2025 773.30K $13.53M Reduce
Q4 2025 885.64K $27.93M Add
Q1 2026 800.04K $23.88M Reduce
Q2 2026 800.17K $44.17M Hold
Q3 2026 716.54K $42.00M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About MBX and 13F data

MBX (MBX BIOSCIENCES INC) is a Health Care company. 61 other funds we track also report a position in MBX — the largest reported positions include Frazier Life Sciences Management, L.P. (US$367.2M), Paradigm Biocapital Advisors LP (US$221.2M), NEA Management Company, LLC (US$199.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding MBX

All MBX fund holders →

FAQ

How long has Parkman Healthcare Partners LLC held MBX?

Parkman Healthcare Partners LLC has disclosed MBX holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

What is Parkman Healthcare Partners LLC's current position in MBX?

As of Q3 2026, Parkman Healthcare Partners LLC holds 716.54K shares of MBX (MBX BIOSCIENCES INC), valued at $42.00M, representing 3.79% of its reported portfolio and ranking #3.

Has Parkman Healthcare Partners LLC been buying or selling MBX?

In the latest 13F filing (Q3 2026), Parkman Healthcare Partners LLC reduced its position in MBX. The position peaked in Q2 2026 at 800.17K shares.

Which other funds hold MBX?

Other major institutional holders of MBX include Frazier Life Sciences Management, L.P., Paradigm Biocapital Advisors LP, NEA Management Company, LLC, among 61 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.